TAXUS II and IV: two-year follow-up TAXUS II Trial TAXUS IV Trial 536 patients with single de novo lesions Lesions <12 mm in length, 3.0-3.5 mm in diameter; Double blind, randomized trial 1,326 patients with single de novo lesions Lesions 10-28 mm in length, 2.5-3.75 mm in diameter; Double blind, randomized trial Paclitaxel-eluting stent Slow-release formulation n=131 Moderate-release formulation n=135 Paclitaxel-eluting stent Slow-release formulation n=662 Bare Stent n= 270 (combined control) Bare Stent n= 652 Endpoints (2 year follow-up): TAXUS II – MACE (97% two-year clinical follow-up) – Late loss (<40% two-year angiographic follow-up) TAXUS IV – MACE – angiographic results not presented Presented at TCT 2004

TAXUS II: Late loss at 6 mo. and two yrs. Two-year angiographic results were available for < 40% of the original TAXUS cohorts, but those available showed little change in late-loss between six months and two years. p=<0.0001 p =NS p =NS mm TCT 2004

TAXUS II: MACE at two years Target lesion revascularization (TLR) and target vessel revascularization (TVR) remained significantly lower in the TAXUS groups, resulting in lower overall MACE. p=0.0178 p=0.0178 p=0.0622 p=0.0126 % p=0.0047 p=0.0006 TCT 2004

TAXUS II: MACE at two years (contin.) Despite reduced TLR and TVR in the TAXUS groups, CABG, MI, and death rates were not statistically different between the TAXUS and control groups. p=NS p=NS p=NS p=NS % TCT 2004

TAXUS IV: MACE at two years TAXUS IV showed similar two-year results: TVR, TLR, and overall MACE remained significantly lower in the TAXUS group. p =<0.0001 p=<0.0001 p =<0.0001 % TCT 2004

TAXUS IV: MACE at two years (contin.) Again, despite reduced overall MACE, rates of death and MI were not significantly different between the two groups. p =NS p=NS % TCT 2004

TAXUS II and IV: two-year follow-up Among patients with single de novo coronary lesions, treatment with a paclitaxel-eluting stent continued to be associated with a reduction in TLR and TVR at 2 years compared with bare stent Consistent with the 6 month and 1 year data, TAXUS stents were not associated with a reduction in the clinical endpoints of death or MI at 2 years. The on-going REALITY trial is a head-to-head trial comparing paclitaxel-eluting stents to sirolimus-eluting stents, which have also been associated with significant reduction in TVR (SIRIUS trial)